B. Riley Has Pessimistic Outlook of DNLI FY2029 Earnings

Key Points

• B. Riley revised its FY2029 earnings per share estimate for Denali Therapeutics from $0.27 to $0.19, while the current consensus is a loss of ($2.71) per share.
• The company's stock saw a slight increase, trading at $14.70, with a market capitalization of $2.15 billion and fluctuating between a 12-month low of $10.57 and a high of $33.33.
• Recent insider sales have taken place, with insiders selling around 501,962 shares in the last three months, indicating a 12.50% ownership by corporate insiders.

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at B. Riley decreased their FY2029 EPS estimates for shares of Denali Therapeutics in a research note issued on Wednesday, August 13th. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of $0.19 for the year, down from their previous forecast of $0.27. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share.

Several other brokerages also recently commented on DNLI. Wedbush reduced their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. TD Cowen raised shares of Denali Therapeutics to a "strong-buy" rating in a research report on Monday, July 28th. Robert W. Baird cut their target price on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. HC Wainwright cut their target price on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Morgan Stanley cut their target price on Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating on the stock in a report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Denali Therapeutics has a consensus rating of "Buy" and an average target price of $33.62.

Denali Therapeutics Trading Down 2.0%

Shares of DNLI stock traded down $0.30 during trading hours on Friday, hitting $14.51. 1,425,496 shares of the company were exchanged, compared to its average volume of 1,410,326. The firm has a market cap of $2.12 billion, a P/E ratio of -5.18 and a beta of 1.36. Denali Therapeutics has a fifty-two week low of $10.57 and a fifty-two week high of $33.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.27 and a current ratio of 10.27. The company has a 50 day simple moving average of $14.29 and a two-hundred day simple moving average of $15.19.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.02. During the same quarter last year, the company posted ($0.59) EPS.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, insider Carole Ho sold 2,937 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the transaction, the insider directly owned 217,391 shares in the company, valued at approximately $2,952,169.78. This trade represents a 1.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alexander O. Schuth sold 2,937 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the transaction, the insider owned 242,346 shares in the company, valued at approximately $3,291,058.68. This trade represents a 1.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 501,962 shares of company stock worth $7,520,799. Corporate insiders own 12.50% of the company's stock.

Institutional Investors Weigh In On Denali Therapeutics

Large investors have recently made changes to their positions in the business. Headlands Technologies LLC purchased a new stake in shares of Denali Therapeutics during the 2nd quarter valued at $26,000. Caitong International Asset Management Co. Ltd increased its position in shares of Denali Therapeutics by 277.0% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock valued at $29,000 after purchasing an additional 1,551 shares during the last quarter. State of Wyoming purchased a new stake in shares of Denali Therapeutics during the 2nd quarter valued at $29,000. Sterling Capital Management LLC increased its position in shares of Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after purchasing an additional 1,516 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Denali Therapeutics during the 1st quarter valued at $41,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.